title: Neurophysiological study on possible protective and therapeutic effects of Sidr (Zizyphus spina-christi L.) leaf extract in male albino rats treated with pentylenetetrazol.
abstract: In this study, anti-convulsant effect of Sidr leaf extract was examined by using pentylenetetrazol (PTZ) model on male albino rat by evaluating the changes in norepinephrine (NE), dopamine (DA) and serotonin (5-HT) contents in different brain regions (cerebellum, brainstem, striatum, cerebral cortex, hypothalamus and hippocampus). The administration of subconvulsive dose of PTZ (40 mg/kg i.p.) every other day for 9 days caused a significant decrease in monoamine content in different brain areas, this is may be due to the increase in nitric oxide levels, although antagonized the GABAA receptors which led to neurotransmitter release so the content is decreased. Administration of PTZ after treatment with Sidr (50 mg/kg i.p.) leaf extract for 3 weeks as a protective group and administration of Sidr leaf extract for 3 weeks after treatment of PTZ as a therapeutic group caused significant increase in NE, DA, and 5-HT contents in all tested brain regions at most of the time intervals studied. This may be due to the presence of peptide and cyclopeptide alkaloids in the extract which inhibit neurotransmitter activity which led to the inhibition of neurotransmitter release. From these results, we can say that the Sidr leaf extract has neuroprotective and therapeutic roles against pentylenetetrazol convulsant effect.
authors: Department of Biology (Zoology), Faculty of Girls Education, Scientific Department, King Abdulaziz University, Jeddah, Saudi Arabia.
authors: Abeer M
authors: AM
authors: Waggas
authors: Reem H
authors: RH
authors: Al-Hasani
keywords: 5-HT; DA; NE; Pentylenetetrazol; Seizure; Zizyphus
references: J Pharmacol Exp Ther. 2001 Sep;298(3):986-95
references: 11504794
references: Prog Neurobiol. 2004 May;73(1):1-60
references: 15193778
references: J Ethnopharmacol. 2004 Nov;95(1):39-45
references: 15374605
references: Fitoterapia. 2001 May;72(4):344-50
references: 11395256
references: Synapse. 1997 Aug;26(4):351-8
references: 9215594
references: Planta Med. 2003 Aug;69(8):692-5
references: 14531016
references: Seizure. 2007 Dec;16(8):691-7
references: 17604186
references: Fundam Clin Pharmacol. 2007 Dec;21(6):583-94
references: 18034659
references: Planta Med. 1976 May;29(3):289-90
references: 948532
references: Epilepsy Res. 2007 Jul;75(2-3):104-11
references: 17544258
references: Phytother Res. 2001 Nov;15(7):593-7
references: 11746840
references: Brain Res. 2000 Jul 28;872(1-2):44-53
references: 10924674
references: J Pharmacol Exp Ther. 1979 Mar;208(3):454-9
references: 34709
references: J Neurochem. 1966 Aug;13(8):655-69
references: 5950056
references: Clin Exp Pharmacol Physiol. 2005 Jul;32(7):574-84
references: 16026518
references: Arch Pharm Res. 2005 Feb;28(2):159-63
references: 15789743
references: Int J Neuropharmacol. 1964 Dec;3:643-9
references: 14347090
references: Gen Pharmacol. 1987;18(6):637-41
references: 3666400
references: Electroencephalogr Clin Neurophysiol. 1972 Mar;32(3):281-94
references: 4110397
references: J Ethnopharmacol. 2002 Jan;79(1):13-6
references: 11744289
references: Afr J Tradit Complement Altern Med. 2007 Feb 16;4(3):248-56
references: 20161885
references: Arch Neurol. 1988 Aug;45(8):884-7
references: 3395262